BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to

BrainStorm Cell Therapeutics Announces Nasdaq

Delisting and Transition to OTCQB

July 17, 2025 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification

from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading

of BrainStorm's common stock on Nasdaq will be suspended at the open of trading on July 18, 2025.

The delisting is a result of the company's non-compliance

with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement.

BrainStorm has already secured approval for its

common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipates

its shares will begin trading on the OTCQB under the same symbol, BCLI, beginning at the open of trading on July 18, 2025, or as soon

as possible thereafter.

Chaim Lebovits, CEO of BrainStorm Cell Therapeutics,

stated, "While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community

that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients. Our pre-arranged transition

to OTCQB ensures continuous trading for our shares and allows us to focus entirely on NurOwn's development. We remain fully dedicated

to our ongoing scientific and clinical programs, including preparations for our pivotal Phase 3b trial under the Special Protocol Assessment

(SPA) agreement with the FDA."

The company confirms that the delisting does not

impact its business operations, its ongoing research and development efforts, or its commitment to its shareholders. BrainStorm will continue

to provide updates on its progress and financial status in compliance with applicable SEC regulations.

NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease

pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells

(MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions

that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver

multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow

or stabilize disease progression.

Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative

diseases. The company's proprietary NurOwn platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting

cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from

both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been

completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn

clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A

genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect"

- a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed

journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive

multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based

platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S.

Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing

IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial

risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment

(SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the

future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking

statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate,"

"believe," "contemplate," "could," "estimate," "expect," "intend," "seek,"

"may," "might," "plan," "potential," "predict," "project," "target,"

"aim," "should," "will" "would," or the negative of these words or other similar expressions,

although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations

and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties

include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital,

BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future

interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly

reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue

reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the

beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking

statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change,

unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable,

we cannot guarantee future results, levels of activity, performance, or achievements.

Phone: +1 646-597-6983

Uri Yablonka, Chief Business Officer

Phone: +1 917-284-2911